Cambridge-based drugs major AstraZeneca has launched a digital health company aimed at both healthcare professionals and patients. Building on collaborations with Parexel and Fortrea, the new company, Evinova, will offer globally-scaled digital products and services to the life sciences and healthcare sector.

Evinova will prioritise bringing to market established and scaled digital technology solutions already being used globally by AstraZeneca to optimise clinical trial design and delivery.

These will include mobile, remote and in-home devices for clinical trials and patient monitoring.

The new company will draw heavily on AstraZeneca’s experience of developing AI-based and algorithmic systems, including predictive digital health algorithms.

Evinova will pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of digital innovations in these areas.

The company will provide established technology solutions to pharma, biotech and CROs to support clinical research globally. The technologies have already been used in the delivery of multiple AstraZeneca-sponsored clinical trials in over 40 countries.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “The future of medicine development can be accelerated with digital solutions. We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.”

Cristina Duran, President of Evinova, said: “We are excited to bring the portfolio of globally-scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the wider life sciences community. We believe this will help propel the sector forward in digital health, as we know healthcare professionals and regulators need digital solutions that work across pharma and support patients broadly. Coming from within the sector and with proven experience, Evinova will be uniquely placed to deliver science-based, evidence-led and human experience-driven solutions with the aim of improving patient experience and outcomes.”

CROs Parexel and Fortrea have entered into agreements to offer Evinova digital health solutions to their customer base. To accelerate industry adoption and sustain and expand the global reach of its digital products, Evinova is collaborating with Accenture and Amazon Web Services.

Evinova will combine clinical and regulatory experience gained at AstraZeneca with its deep expertise in digital technology spanning strategy and development, digital product development, data science and AI, user experience design and behavioural science. In addition to digital solutions, Evinova will offer custom scientific solutions, including remote patient monitoring and novel endpoint solutions, as well as trial design and consulting services.